专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08569542B2 Use of docosatrienes, resolvins, and their stable analogs in the treatment of airway diseases and asthma 有权
标题翻译：使用二十二烷，解冻素及其稳定的类似物治疗气道疾病和哮喘
公开(公告)号：US08569542B2
公开(公告)日：2013-10-29
申请号：US13007600
申请日：2011-01-15
申请人： Charles N. Serhan , Bruce D. Levy
发明人： Charles N. Serhan , Bruce D. Levy
IPC分类号： C07C57/02 , C07C69/52 , A01N37/06 , A01N37/00
CPC分类号： C07C59/42 , A61K31/202 , A61K31/275 , A61K31/445 , A61K31/495 , A61K31/537 , A61K31/551 , A61K31/655 , C07C59/48 , C07F7/1804
摘要： The present invention is generally drawn to novel isolated therapeutic agents, termed resolvins, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (PUFA) such as eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), cyclooxygenase-II (COX-2) and an analgesic, such as aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy EPA or DHA compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- or tri-hydroxy derivatives of EPA or DHA (resolvins) that diminish, prevent, or eliminate inflammation or PMN migration, for example. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification.
摘要翻译：本发明一般涉及由膳食ω-3多不饱和脂肪酸（PUFA）如二十碳五烯酸（EPA）或二十二碳六烯酸（DHA），环氧合酶II（COX）之间的相互作用产生的新型分离的治疗剂，称为溶血素 -2）和止痛剂，例如阿司匹林（ASA）。令人惊讶的是，在合适的环境中仔细分离由组分组合产生的化合物，提供了具有独特结构和生理特性的二羟基EPA或DHA化合物。因此，本发明提供了例如减少，预防或消除炎症或PMN迁移的许多新的有用的EPA或DHA（resolvins）治疗二 - 或三羟基衍生物。本发明还提供了用于本说明书中公开的化合物的药物用途，制备方法和包装药物的方法。

2. 发明授权

US08440718B2 Modulation of inflammation related to columnar epithelia 失效
公开(公告)号：US08440718B2
公开(公告)日：2013-05-14
申请号：US10762388
申请日：2004-01-22
申请人： James L. Madara , Charles N. Serhan , Sean P. Colgan
发明人： James L. Madara , Charles N. Serhan , Sean P. Colgan
IPC分类号： A61K31/23
CPC分类号： G01N33/5088 , A61K31/20 , A61K31/215 , A61K31/216 , A61K31/22 , A61K31/23 , A61K31/232 , A61K38/00 , C07C59/42 , C07C59/46 , C07C59/48 , C07C59/56 , C07C59/58 , C07C59/68 , C07C69/732 , C07C69/734 , C07C69/736 , C07F7/081 , C07K14/705 , C07K16/18 , C12P1/00 , C12R1/91 , G01N33/5047 , Y02A50/481
摘要： This invention provides pharmaceutical compositions containing lipoxin compounds and therapeutic uses for the compounds in treating or preventing a disease or condition associated with columnar epithelial inflammation. The invention also discloses methods for screening for compounds useful in preventing columnar epithelial inflammation.

3. 发明授权

US08273792B2 Anti-inflammatory actions of neuroprotectin D1/protectin D1 and it's natural stereoisomers 有权
标题翻译：神经保护素D1 /保护素D1的抗炎作用及其天然立体异构体
公开(公告)号：US08273792B2
公开(公告)日：2012-09-25
申请号：US12089141
申请日：2006-10-03
申请人： Charles N. Serhan , Nicos A. Petasis , Bruce D. Levy
发明人： Charles N. Serhan , Nicos A. Petasis , Bruce D. Levy
IPC分类号： A01N37/06 , C07C57/00 , C07C69/73 , C07C59/00
CPC分类号： A61K31/202 , C07C59/42 , C07C69/732
摘要： (Neuro)protectin D1 (1OR,17S-dihydroxy-docosa-4Z,7Z,11E,13E,15Z,19Z-hexaenoic acid) and 15,16-dehydro-PD1 and their derivatives are useful in the treatment of airway inflammation, especially asthma.
摘要翻译：（Neuro）保护素D1（10R，17S-二羟基 - 二十二氢-4Z，7Z，11E，13E，15Z，19Z-六烯酸）和15,16-脱氢-PD1及其衍生物可用于治疗气道炎症，特别是哮喘。

4. 发明申请

US20120010286A1 PREVENTION OF NEUTROPHIL RECRUITMENT 审中-公开
标题翻译：预防中耳炎招募
公开(公告)号：US20120010286A1
公开(公告)日：2012-01-12
申请号：US13236357
申请日：2011-09-19
申请人： Charles N. Serhan
发明人： Charles N. Serhan
IPC分类号： A61K31/235 , A61P29/00
CPC分类号： C07C69/736
摘要： Aspirin (ASA) triggers a switch in the biosynthesis of lipid mediators, inhibiting prostanoid production and initiating 15-epi-lipoxin generation, through the acetylation of cyclooxygenase II.
摘要翻译：通过环氧合酶II的乙酰化，阿司匹林（ASA）引发脂质介质的生物合成转换，抑制前列腺素类产生和引发15表面脂蛋白的产生。

5. 发明申请

US20110288317A1 14-HYDROXY-DOCOSAHEXAENOIC ACID COMPOUNDS 有权
标题翻译： 14-羟基 - 二氧六环酸化合物
公开(公告)号：US20110288317A1
公开(公告)日：2011-11-24
申请号：US13119096
申请日：2009-09-15
申请人： Charles N. Serhan , Rong Yang
发明人： Charles N. Serhan , Rong Yang
IPC分类号： C07C59/42 , C07D303/38
CPC分类号： C07D303/38 , A23K20/158 , A61K8/365 , A61K8/37 , A61K8/4973 , A61K31/202 , A61Q5/006 , A61Q19/00 , A61Q19/08 , C07C59/42 , C07C59/58 , C07C69/732 , C07D303/12 , Y02P20/55
摘要： The invention describes novel 14-hydroxy docosahexaenoic acid (DHA) analogues, their preparation, isolation, identification, purification and uses thereof.
摘要翻译：本发明描述了新型的14-羟基二十二碳六烯酸（DHA）类似物，它们的制备，分离，鉴定，纯化和用途。

6. 发明授权

US07915311B2 Approach to anti-microbial host defense with molecular shields with lipoxin compounds 有权
公开(公告)号：US07915311B2
公开(公告)日：2011-03-29
申请号：US11837693
申请日：2007-08-13
申请人： Charles N. Serhan , Sean P. Colgan
发明人： Charles N. Serhan , Sean P. Colgan
IPC分类号： A01N37/00 , A01N37/02 , A61K31/215 , A61K31/22 , A61K31/23
摘要： Methods to cause tissue, such as mucosal cells, to express increased amounts of bactericidal permeability increasing protein (BPI) are described. The BPI inducing agents include, for example, lipoxin compounds.

7. 发明授权

US07825271B2 Lipoxin compounds and their use in treating cell proliferative disorders 失效
公开(公告)号：US07825271B2
公开(公告)日：2010-11-02
申请号：US11837824
申请日：2007-08-13
申请人： Charles N. Serhan
发明人： Charles N. Serhan
IPC分类号： C07C57/00
CPC分类号： C07C69/736 , A61K31/202 , A61K31/232 , A61K31/557 , A61K31/60 , C07C59/42 , C07C69/587 , C07C69/732 , C07C69/734 , A61K2300/00
摘要： Compounds having the active site of natural lipoxins, but a longer tissue half-life are disclosed. In particular, 15-epi-lipoxins and their use in ameliorating undesired cell proliferation, which characterizes diseases such as cancer, are also disclosed.

8. 发明申请

US20100105772A1 USE OF NOVEL LIPID MEDIATORS TO INHIBIT ANGIOGENESIS 审中-公开
标题翻译：使用新型脂质介质抑制血管生成
公开(公告)号：US20100105772A1
公开(公告)日：2010-04-29
申请号：US12430287
申请日：2009-04-27
申请人： Charles N. Serhan , Reza Dana , Yiping Jin
发明人： Charles N. Serhan , Reza Dana , Yiping Jin
IPC分类号： A61K31/235 , A61K31/202
CPC分类号： A61K31/202 , A61K31/235
摘要： The present invention is generally drawn to novel isolated therapeutic agents, termed lipoxins, generated from the interaction between a dietary omega-6 polyunsaturated fatty acid (PUFA) such as arachidonic acid (AA), oxygenases and the analgesic aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy containing derivatives of AA containing compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- and tri-hydroxy derivatives of AA (lipoxins, aspirin-triggered epi-lipoxins) that diminish, prevent, or eliminate NV, hemangiogenesis and/or angiogenic condition(s) of corneal tissue. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification.
摘要翻译：通常，本发明涉及由膳食ω-6多不饱和脂肪酸（PUFA）如花生四烯酸（AA），加氧酶和止痛阿司匹林（ASA）之间的相互作用产生的新型分离的治疗剂，称为脂氧素。令人惊讶的是，在合适的环境中仔细分离由组分组合产生的化合物，提供具有独特结构和生理特性的含AA化合物的二羟基和三羟基衍生物。因此，本发明提供了减少，预防或消除角膜组织的NV，血管生成和/或血管生成状态的许多新的有用的治疗性二羟基和三羟基衍生物（脂氧素，阿司匹林触发的表皮脂氧素）。本发明还提供了用于本说明书中公开的化合物的药物用途，制备方法和包装药物的方法。

9. 发明申请

US20100016432A1 RESOLVINS: BIOTEMPLATES FOR NOVEL THERAPEUTIC INTERVENTIONS 审中-公开
标题翻译：解决方案：新型治疗干预的生物技术
公开(公告)号：US20100016432A1
公开(公告)日：2010-01-21
申请号：US12499528
申请日：2009-07-08
申请人： CHARLES N. SERHAN
发明人： CHARLES N. SERHAN
IPC分类号： A61K31/202 , A61P29/00
CPC分类号： A61K31/202 , C07C59/42 , C07C59/48 , C07C69/732 , C07F7/1804
摘要： The present invention is generally drawn to novel isolated therapeutic agents, termed resolving, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (PUFA) such as eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), cyclooxygenase-II (COX-2) and an analgesic, such as aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy EPA or DHA compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- or tri-hydroxy derivatives of EPA or DHA (resolvins) that diminish, prevent, or eliminate inflammation or PMN migration, for example. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification.
摘要翻译：本发明一般涉及由膳食ω-3多不饱和脂肪酸（PUFA）如二十碳五烯酸（EPA）或二十二碳六烯酸（DHA），环氧合酶II（COX）之间的相互作用产生的称为拆分的新型分离治疗剂 -2）和止痛剂，例如阿司匹林（ASA）。令人惊讶的是，在合适的环境中仔细分离由组分组合产生的化合物，提供了具有独特结构和生理特性的二羟基EPA或DHA化合物。因此，本发明提供了例如减少，预防或消除炎症或PMN迁移的许多新的有用的EPA或DHA（resolvins）治疗二 - 或三羟基衍生物。本发明还提供了用于本说明书中公开的化合物的药物用途，制备方法和包装药物的方法。

10. 发明申请

US20090258945A1 Lipoxin Compounds and Their Use in Treating Cell Proliferative Disorders 失效
标题翻译：脂氧素化合物及其在治疗细胞增殖性疾病中的应用
公开(公告)号：US20090258945A1
公开(公告)日：2009-10-15
申请号：US11743022
申请日：2007-05-01
申请人： Charles N. Serhan
发明人： Charles N. Serhan
IPC分类号： A61K31/202
CPC分类号： C07C69/736 , A61K31/202 , A61K31/232 , A61K31/557 , A61K31/60 , C07C59/42 , C07C69/587 , C07C69/732 , C07C69/734 , A61K2300/00
摘要： Compounds having the active site of natural lipoxins, but a longer tissue half-life are disclosed. In particular, 15-epi-lipoxins and their use in ameliorating undesired cell proliferation, which characterizes diseases such as cancer, are also disclosed.
摘要翻译：公开了具有天然脂氧素活性位点但具有较长组织半衰期的化合物。特别地，还公开了15表面脂蛋白及其在改善诸如癌症等疾病特征的不想要的细胞增殖中的用途。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式